COURTING Cipla

PHARMA MAJOR CIPLA HAS GENERATED CONSIDERABLE INTEREST FROM PRIVATE EQUITY PLAYERS. WHAT MAKES IT SUCH AN ALLURING PROSPECT, AND WHAT DOES THE FUTURE HOLD FOR THIS STORIED COMPANY?

BY NEETU CHANDRA SHARMA

CIPLA LTD, BEST known as an innovator that broke the monopolies of multinational pharmaceutical giants to sell affordable drugs for AIDS and the flu, has suddenly become the pill that big investors and rivals want to pop. Set up in 1935 by Khwaja Abdul Hamied, a chemist and disciple of M.K. Gandhi, Cipla is also a star of India’s freedom movement with a storied history. Today, Blackstone, the world’s largest private equity group, is looking for the entire promoters’ stake of 33.47 per cent owned by the Hamied family. So are Indian rivals Torrent Pharmaceuticals and Dr. Reddy’s Laboratories. Yusuf Khwaja Hamied, 87, the founder’s son and current Chairman, is non-committal. Hamied, a doctorate in chemistry from Cambridge University who took over in 1972, has had a long innings, steering Cipla from the…

You're reading a preview of

Business Today (Digital) - 1 Issue, 29 October 2023

DiscountMags is a licensed distributor (not a publisher) of the above content and Publication through Zinio LLC. Accordingly, we have no editorial control over the Publications. Any opinions, advice, statements, services, offers or other information or content expressed or made available by third parties, including those made in Publications offered on our website, are those of the respective author(s) or publisher(s) and not of DiscountMags. DiscountMags does not guarantee the accuracy, completeness, truthfulness, or usefulness of all or any portion of any publication or any services or offers made by third parties, nor will we be liable for any loss or damage caused by your reliance on information contained in any Publication, or your use of services offered, or your acceptance of any offers made through the Service or the Publications. For content removal requests, please contact Zinio.